Browsing by Author Robinson, Andrew G.

Jump to: 0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 中
Showing results 1 to 5 of 5
TitleAuthor(s)Issue Date
 
Five-Year Outcomes with Pembrolizumab Versus Chemotherapy for Metastatic Non–Small-Cell Lung Cancer with PD-L1 Tumor Proportion Score ‡ 50%
Journal:Journal of Clinical Oncology
Reck, MartinRodríguez-Abreu, DelvysRobinson, Andrew G.Hui, RinaCsöszi, TiborFülöp, AndreaGottfried, MayaPeled, NirTafreshi, AliCuffe, SineadO’Brien, MaryRao, SumanHotta, KatsuyukiLeal, Ticiana A.Riess, Jonathan W.Jensen, ErinZhao, BinPietanza, M. CatherineBrahmer, Julie R.
2021
 
Health-related quality-of-life results for pembrolizumab versus chemotherapy in advanced, PD-L1-positive NSCLC (KEYNOTE-024): a multicentre, international, randomised, open-label phase 3 trial
Journal:The Lancet Oncology
Brahmer, Julie R.Rodríguez-Abreu, DelvysRobinson, Andrew G.Hui, RinaCsőszi, TiborFülöp, AndreaGottfried, MayaPeled, NirTafreshi, AliCuffe, SineadO'Brien, MaryRao, SumanHotta, KatsuyukiZhang, JinLubiniecki, Gregory M.Deitz, Anne C.Rangwala, ReshmaReck, Martin
2017
 
Outcomes With Pembrolizumab Monotherapy in Patients With Programmed Death-Ligand 1–Positive NSCLC With Brain Metastases: Pooled Analysis of KEYNOTE-001, 010, 024, and 042
Proceeding/Conference:JTO Clinical and Research Reports
Mansfield, Aaron S.Herbst, Roy S.de Castro, GilbertoHui, RinaPeled, NirKim, Dong WanNovello, SilviaSatouchi, MiyakoWu, Yi LongGaron, Edward B.Reck, MartinRobinson, Andrew G.Samkari, AymanPiperdi, BilalEbiana, VictoriaLin, JianxinMok, Tony S.K.
2021
 
Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer
Journal:New England Journal of Medicine
Reck, MartinRodriguez-Abreu, DelvysRobinson, Andrew G.Hui, RinaCsöszi, TiborFülöp, AndreaGottfried, MayaPeled, NirTafreshi, AliCuffe, SineadO'Brien, MaryRao, SumanHotta, KatsuyukiLeiby, Melanie A.Lubiniecki, Gregory M.Shentu, YueRangwala, ReshmaBrahmer, Julie R.
2016
 
Updated analysis of KEYNOTE-024: Pembrolizumab versus platinum-based chemotherapy for advanced non–small-cell lung cancer with PD-L1 tumor proportion score of 50% or greater
Journal:Journal of Clinical Oncology
Reck, MartinRodríguez-Abreu, DelvysRobinson, Andrew G.Hui, RinaCsoszi, TiborFülöp, AndreaGottfried, MayaPeled, NirTafreshi, AliCuffe, SineadO’Brien, MaryRao, SumanHotta, KatsuyukiVandormael, KristelRiccio, AntonioYang, JingCatherine Pietanza, M.Brahmer, Julie R.
2019
Showing results 1 to 5 of 5